Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C21H25FN6O2 |
Molar mass | 412.469 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(verify) |
Ro48-6791 is a drug, an imidazo benzodiazepine derivative developed by Hoffman-LaRoche in the 1990s. [1]
Ro48-6791 was developed as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures. Ro48-6791 has properties similar to those of midazolam, being water-soluble, with a fast onset and short duration of action. It is 4-6x more potent than midazolam, [2] and slightly shorter acting, [3] and produces similar side effects such as sedation and amnesia.
It was tested up to Phase II human trials, but while it produced less respiratory depression than propofol, it had a longer recovery time and was deemed not to have any significant advantages over the older drug. [4] Similarly when Ro48-6791 was compared to midazolam, it had similar efficacy, higher potency and a shorter recovery time, but produced less of a synergistic effect on opioid-induced analgesia and produced more severe side effects such as dizziness after the procedure. [5] Consequently, it was dropped from clinical development, [6] although it is still used in scientific research. [7]
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C21H25FN6O2 |
Molar mass | 412.469 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(verify) |
Ro48-6791 is a drug, an imidazo benzodiazepine derivative developed by Hoffman-LaRoche in the 1990s. [1]
Ro48-6791 was developed as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures. Ro48-6791 has properties similar to those of midazolam, being water-soluble, with a fast onset and short duration of action. It is 4-6x more potent than midazolam, [2] and slightly shorter acting, [3] and produces similar side effects such as sedation and amnesia.
It was tested up to Phase II human trials, but while it produced less respiratory depression than propofol, it had a longer recovery time and was deemed not to have any significant advantages over the older drug. [4] Similarly when Ro48-6791 was compared to midazolam, it had similar efficacy, higher potency and a shorter recovery time, but produced less of a synergistic effect on opioid-induced analgesia and produced more severe side effects such as dizziness after the procedure. [5] Consequently, it was dropped from clinical development, [6] although it is still used in scientific research. [7]